342 related articles for article (PubMed ID: 37644916)
1. Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer.
Tong L; Yu X; Wang S; Chen L; Wu Y
Breast Cancer (Dove Med Press); 2023; 15():647-658. PubMed ID: 37644916
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in targeted strategies for triple-negative breast cancer.
Zhu S; Wu Y; Song B; Yi M; Yan Y; Mei Q; Wu K
J Hematol Oncol; 2023 Aug; 16(1):100. PubMed ID: 37641116
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
Gupta GK; Collier AL; Lee D; Hoefer RA; Zheleva V; Siewertsz van Reesema LL; Tang-Tan AM; Guye ML; Chang DZ; Winston JS; Samli B; Jansen RJ; Petricoin EF; Goetz MP; Bear HD; Tang AH
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32846967
[TBL] [Abstract][Full Text] [Related]
4. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
Front Oncol; 2022; 12():919072. PubMed ID: 35795050
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in triple-negative breast cancer.
Katz H; Alsharedi M
Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
[TBL] [Abstract][Full Text] [Related]
6. Targeted Therapeutic Strategies for Triple-Negative Breast Cancer.
Li Y; Zhan Z; Yin X; Fu S; Deng X
Front Oncol; 2021; 11():731535. PubMed ID: 34778045
[TBL] [Abstract][Full Text] [Related]
7. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
8. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M;
Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662
[TBL] [Abstract][Full Text] [Related]
9. Immunological therapy: A novel thriving area for triple-negative breast cancer treatment.
Wang X; Qi Y; Kong X; Zhai J; Li Y; Song Y; Wang J; Feng X; Fang Y
Cancer Lett; 2019 Feb; 442():409-428. PubMed ID: 30419345
[TBL] [Abstract][Full Text] [Related]
10. Untangling Triple-Negative Breast Cancer Molecular Peculiarity and Chemo-Resistance: Trailing Towards Marker-Based Targeted Therapies.
Kanwal B
Cureus; 2021 Jul; 13(7):e16636. PubMed ID: 34458041
[TBL] [Abstract][Full Text] [Related]
11. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
[TBL] [Abstract][Full Text] [Related]
12. Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021.
Bou Zerdan M; Ghorayeb T; Saliba F; Allam S; Bou Zerdan M; Yaghi M; Bilani N; Jaafar R; Nahleh Z
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267561
[TBL] [Abstract][Full Text] [Related]
13. Target-Oriented Classification of Triple-negative Breast Cancer.
Mizumoto S; Inubushi S; Miki M; Nakamura H; Baba M; Yamashita Y; Yamamoto M; Inoue S; Tanino H; Kunihisa T
Anticancer Res; 2023 Nov; 43(11):5067-5072. PubMed ID: 37909966
[TBL] [Abstract][Full Text] [Related]
14. Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer.
Kelly CM; Buzdar AU
Drugs; 2013 May; 73(6):505-15. PubMed ID: 23605692
[TBL] [Abstract][Full Text] [Related]
15. Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer.
Zhang Z; Zhang R; Li D
Biologics; 2023; 17():113-128. PubMed ID: 37767463
[TBL] [Abstract][Full Text] [Related]
16. Triple-negative breast cancer: A run-through of features, classification and current therapies.
Manjunath M; Choudhary B
Oncol Lett; 2021 Jul; 22(1):512. PubMed ID: 33986872
[TBL] [Abstract][Full Text] [Related]
17. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
Nagayama A; Vidula N; Bardia A
Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
[TBL] [Abstract][Full Text] [Related]
18. Triple-negative breast cancer molecular subtyping and treatment progress.
Yin L; Duan JJ; Bian XW; Yu SC
Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
[TBL] [Abstract][Full Text] [Related]
19. State of art of advanced triple negative breast cancer.
Khosravi-Shahi P; Cabezón-Gutiérrez L; Aparicio Salcedo MI
Breast J; 2019 Sep; 25(5):967-970. PubMed ID: 31155832
[TBL] [Abstract][Full Text] [Related]
20. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
